Teva Pharmaceutical's stock experienced a significant pre-market plunge of 8.08% on Wednesday, indicating negative investor sentiment ahead of the trading session.
The sharp decline follows the company's release of its financial guidance for the full year 2026, which fell short of analyst expectations. Teva expects revenue in the range of $16.4 billion to $16.8 billion, below the FactSet consensus estimate of $17.12 billion. Additionally, the company projected non-GAAP earnings per share between $2.57 and $2.77, which also trails the FactSet estimate of $2.81.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments